Skip to content

A clinical trial to study the effects of glutamine (an amino acid)supplementation in patients with acute pancreatitis.

Effect of glutamine on gut permeability in acute pancreatitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000945
Enrollment
60
Registered
2010-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pateints admitted to the deptt of Gastroenterology AIIMS with acute pancreatitis

Interventions

Intervention1: Oral Glutamine: 20gm in two doses of 10 gm each for 7 days Control Intervention1: oral whey protein: 20 gms in 2 doses of 10 gm each for 7 days

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients admitted to gastroenterology ward of AIIMS with acute pancreatitis defined by compatible abdominal pain associated with raised S amylase >3xULN and suggestive imaging shall be included.Among those with severe acute pancreatitis shall be included in the study

Exclusion criteria

Exclusion criteria: <18 yrs to > 80 yrs Renal failure at onset or within 7 days of study Patients who had already received enteral nutrition prior to inclusion in the study. Absence of - Advanced. Chronic Liver Disease, - Inflammatory Bowel Disease - Celiac disease - Cystic fibrosis - Major surgery - Patient already on NSAIDS - Pregnancy - Lack of informed consent

Design outcomes

Primary

MeasureTime frame
To evaluate change in intestinal permeability (IP) in patients with SAP at onset followed by repeat evaluation of IP after oral Glutamine supplementation compared to those who receive whey protein. Change in endotoxin levels (markers of endotoxemia IgG and IgM) in both groups after supplementation. Timepoint: 7 days after supplementation, Tests will be done pre supplementation and 7 days after supplementation.

Secondary

MeasureTime frame
biochemiA. Clinical Infectious complication Total hospital stay Other infectious complication Duration of ICU stay B. Biochemical parameters CRP Pre-albumin Timepoint: for clinical secondary outcome entire hospital stay will be included for biochemical parameters will be done prior to and 7 days after supplementation

Countries

India

Contacts

Public ContactDr Anoop Saraya
anoopgetrial@yahoo.com011-26593294

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026